Andrew H. Talal

Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial

Zobair M. Younossi, Vlad Ratziu, Rohit Loomba et al. · The Lancet · 2019 · 1.2K citations · Full text

Medicine, Internal Medicine, Pharmacology +8

Quantifying Residual HIV-1 Replication in Patients Receiving Combination Antiretroviral Therapy

Linqi Zhang, Bharat Ramratnam, Klara Tenner‐Racz et al. · New England Journal of Medicine · 1999 · 824 citations · Full text

Life Sciences, Immunology, Infectious Diseases +14

Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials

Stephen A. Harrison, Vincent Wai‐Sun Wong, Takeshi Okanoue et al. · Journal of Hepatology · 2020 · 466 citations

Medicine, Internal Medicine, Pharmacotherapy +12

Neutralizing antibody response during acute and chronic hepatitis C virus infection

Carine Logvinoff, Marian Major, David Oldach et al. · Proceedings of the National Academy of Sciences · 2004 · 421 citations · Full text

Life Sciences, Immunology, Infectious Diseases +13

Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients

Thomas Kuntzen, Andrew Berical, Niall J. Lennon et al. · Hepatology · 2008 · 345 citations · Full text

Life Sciences, Infectious Diseases, Molecular Genetics +17